X
Record #52985

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Publisher
Elsevier
Original paper date
Sep 29, 2017
Institution
German Center for Lung Research (DZL), Giessen, Germany · University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany · Department of Medicine, Imperial College London, London, UK · Assistance Publique—Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France · INSERM U-999, Le Kremlin-Bicêtre, France · Department of Cardio-Thoracic and Vascular Surgery, Heart and Lung Transplantation and Pulmonary Hypertension Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, Italy · Division of Pulmonary and Critical Care Medicine, University of California San Diego, La Jolla, CA, USA · National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK · National Heart & Lung Institute, Imperial College London, London, UK · Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK · State Key Lab of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China · Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, CA, USA · Actelion Pharmaceuticals, Allschwil, Switzerland · Department of Thoracic Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany
Open access
No
Article type
Clinical Study
Broad categories
(HSC) Medicine - Cardiovascular(HSC) Medicine - Pharmacology(HSC) Medicine - Pulmonology
Notes from Retraction Watch

see: https://www.sciencedirect.com/science/article/abs/pii/S2213260024000274

Citation lifecycle

How this paper is being cited

Pre-retraction
158
Same day
0
Post-retraction
28
% post-retraction
15.1%
~24.4 citations/yr before retraction · ~11.3 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse